107 related articles for article (PubMed ID: 12684909)
1. Prognostic factors in severe exacerbation of chronic hepatitis B.
Yuen MF; Sablon E; Hui CK; Li TM; Yuan HJ; Wong DK; Doutreloigne J; Bogaerts V; Wong BC; Fan ST; Lai CL
Clin Infect Dis; 2003 Apr; 36(8):979-84. PubMed ID: 12684909
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
3. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
4. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
[TBL] [Abstract][Full Text] [Related]
5. Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B.
Kusumoto K; Yatsuhashi H; Nakao R; Hamada R; Fukuda M; Tamada Y; Taura N; Komori A; Daikoku M; Hamasaki K; Nakao K; Ishibashi H; Miyakawa Y; Eguchi K
J Gastroenterol Hepatol; 2008 May; 23(5):790-3. PubMed ID: 18410611
[TBL] [Abstract][Full Text] [Related]
6. Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation.
Tsai WL; Lo GH; Hsu PI; Lai KH; Lin CK; Chan HH; Chen WC; Cheng JS; Liu YC; Huang TS; Ger LP; Lin HH
Scand J Gastroenterol; 2008; 43(2):196-201. PubMed ID: 18224565
[TBL] [Abstract][Full Text] [Related]
7. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
8. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M
Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585
[TBL] [Abstract][Full Text] [Related]
10. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
[TBL] [Abstract][Full Text] [Related]
13. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong.
Yuen MF; Sablon E; Tanaka Y; Kato T; Mizokami M; Doutreloigne J; Yuan HJ; Wong DK; Sum SM; Lai CL
J Hepatol; 2004 Jul; 41(1):119-25. PubMed ID: 15246217
[TBL] [Abstract][Full Text] [Related]
15. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
[TBL] [Abstract][Full Text] [Related]
16. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation.
Yuen MF; Sablon E; Wong DK; Yuan HJ; Wong BC; Chan AO; Lai CL
Clin Infect Dis; 2003 Aug; 37(4):593-7. PubMed ID: 12905145
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus mutations associated with in situ expression of hepatitis B core antigen, viral load and prognosis in chronic hepatitis B patients.
Zhu R; Zhang HP; Yu H; Li H; Ling YQ; Hu XQ; Zhu HG
Pathol Res Pract; 2008; 204(10):731-42. PubMed ID: 18597951
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma.
Hiraoka A; Michitaka K; Kumagi T; Kurose K; Uehara T; Hirooka M; Yamashita Y; Kubo Y; Miyaoka H; Iuchi H; Okada S; Ohmoto M; Yamamoto K; Horiike N; Onji M
Oncol Rep; 2005 Jun; 13(6):1159-63. PubMed ID: 15870937
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
